Research Article

Identification of Synovial Fibroblast-Associated Neuropeptide Genes and m6A Factors in Rheumatoid Arthritis Using Single-Cell Analysis and Machine Learning

Jianwei Xiao,¹ Xu Cai,¹ Rongsheng Wang,² Weijian Zhou,³ and Zhizhong Ye¹

¹Shenzhen Futian Hospital for Rheumatic Diseases, China

²Department of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional and Western Medicine, China

³Rheumatism Dept. Yunnan Provincial Hospital of Traditional Chinese Medicine, China

Correspondence should be addressed to Zhizhong Ye; 20161106559@mails.imnu.edu.cn

Received 7 November 2021; Revised 13 December 2021; Accepted 3 January 2022; Published 9 February 2022

Academic Editor: Yuzhen Xu

Copyright © 2022 Jianwei Xiao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. Synovial fibroblasts (SFs) play an important role in the development and progression of rheumatoid arthritis (RA). However, the pathogenic mechanism of SFs remains unclear. The objective of this study was to investigate how neuropeptides and N6-methyladenosine (m6A) played an important role in the underlying pathogenic processes of SFs that contribute to the development of RA. **Methods.** Single-cell RNA sequencing data were examined using single-cell analysis and machine learning. SF subgroups were identified based on the clustering and annotation results of the single-cell analysis. Moreover, cell–cell communication was used to analyse neuropeptide-related receptor and ligand pairs on the surface of SF cell membranes. Machine learning was used to explore the m6A factors acting on these neuropeptide genes. **Results.** NPR3, GHR, BDKRB2, and CALCRL, four neuropeptide genes, were shown to be differently expressed among SF subgroups. Further investigation of receptor–ligand interactions found that NPR3 (in conjunction with NPPC, OSTN, NPPB, and NPPA) and GHR (in conjunction with GH1 and GH2) may have a role in SF interactions. As predicted by machine learning, *IGFBP2* and *METTL3* were identified as key factors regulating m6A of *NPR3* and *GHR*. The expression levels and enrichment pathways of *METTL3* and *IGFBP2* were different among SF subgroups. **Conclusions.** Single-cell analysis and machine learning efficiently identified neuropeptide genes and m6A factors that perform important regulatory functions in RA. Our strategy may provide a basis for future studies to identify pathogenic cell subpopulations and molecular mechanisms in RA and other diseases.

1. Introduction

Rheumatoid arthritis (RA) is a chronic immune disease that primarily affects the synovial lining of joints and affects roughly 1% of the world's population [1, 2]. RA can present with a variety of clinical symptoms and modes of progression. The etiology of RA is unclear. It is usually thought to occur in response to a combination of genetic susceptibility and environmental factors. The typical pathology of RA is the proliferation of synovial fibroblasts (SF), also termed fibroblast-like synoviocytes (FLS), in the joints and the formation of granulations that erode and destroy the articular cartilage [3]. SF maintains the persistence of inflammation and is driven by multiple epimodification modalities [4].

In addition, fibroblasts can switch from early immunosuppressive to stimulatory in response to relevant factors to promote RA development [5]. Therefore, SF may serve as a potential and safe therapeutic target [6].

Several previous studies have explored the relationship between neuropeptides and RA. High NPY levels are an independent marker of RA activity [7]. Patients with RA have increased levels of SP in synovial fluid and serum, and NK-1R was adjusted upward in SF [8]. Symptoms of the disease can be reduced after sympathetic tone decreases in RA patients [9]. In addition, both excessive and insufficient production of neuropeptides may be harmful to joint cartilage [10]. The treatment carried out for neuropeptides also showed good results in arthritis experiments in mice

[11]. Therefore, neuropeptides may play an important role in the development of RA.

Epistatic modifications can stably alter gene expression without changing the nucleic acid base ordering. DNA methylation and histone modifications all play important roles in RA [12]. N6-Methyladenosine (m6A) is the most abundant form of mRNA modification, and it plays an important regulatory role in cancer as well as immune diseases in the form of posttranscriptional modifications [13–15]. RNA methylation involves a variety of m6A readers, writers, and erasers [16, 17]. These enzymes or factors are involved in almost every process of mRNA metabolism, as well as playing a role in various physiological processes [18]. RNA m6A is similarly involved in several immune functions, including immune recognition and activation, as well as cell fate determination [19]. The relationship between RA, as a systemic autoimmune disease, and m6A remains unclear [20].

In summary, both neuropeptides and m6A may play an important role in the development of RA. However, no research has been done at the interaction between neuropeptides and m6A in RA. The development of single-cell analytic methods has resulted in more efficient research of SF at the cellular level in recent years [21]. Moreover, bioinformatics approaches such as cellular communication enable the prediction of cell-cell interaction relationships [22]. As a result, we attempted to examine the relationship between neuropeptides and m6A in RA through single-cell analysis and machine learning techniques.

2. Materials and Methods

2.1. Data Acquisition and Preprocessing. By searching “rheumatoid arthritis (RA)” in the GEO database, we obtained two datasets (including GSE109449 and GSE21959). GSE109449 contains synovial fibroblast transcript data from two RA and two OA (osteoarthritis) patients [23]. The single-cell RNA-seq data obtained were used to analyse the relationships between subpopulations of fibroblasts. The GSE21959 dataset provided bulk RNA-seq data from six RA and six adult donors’ synovial tissues. Based on the GSE21959 dataset, differentially expressed genes between RA and HC were screened [24]. The data from single-cell RNA-seq was filtered to ensure that genes were expressed in at least three cells and that each cell had at least 200 genes expressed. Afterwards, quality control of the RNA data was assessed and compared across samples. RNA data was normalised by log transformation and feature scaling. “edgeR” was then applied to the bulk RNA count for differentially expressed gene analysis [25]. In addition, we performed real-time RT-PCR (qRT-PCR) validation in a clinical cohort at our hospital. Informed consent was obtained from all our patients. The study was in line with the principles set out in the “Helsinki Manifesto.”

2.2. Neuropeptide-Related Genes and m6A Factors. Neuropeptide-related genes included in this study included both neuropeptides and neuropeptide receptors. Through a literature review, 53 neuropeptide-related genes were included

in this study (NPY, NPY1R, NPY2R, NPY4R, NPY5R, CALCA, CALCB, CALCR, CALCRL, CRCP, ADCYAPI, ADCYAPIR1, PACAP, GAL, GALR1, GALR2, VIP, VIPR1, VIPR2, NPPA, NPPA-AS1, NPR1, NPR3, NPR2, NPPB, NPPC, PDYN, PDYN-AS1, AGT, AGTR1, AGTR2, SP, SN, ENK, EP, DYN, SIGMAR1, OPRK1, OPRD1, OPRM1, OPRL1, TACR1, BDKRB2, BDKRB1, NPSR1, NTS, NTSR1, NTSR2, GH, GHR, PRL, PRLR, and TAFA4). In addition, 23 m6A factors, including 8 writers, 13 readers, and two erasers, were also incorporated.

2.3. Single-Cell Data Analysis. For single-cell analysis, we utilized the Seurat program (version 4.0.4), which included data cleaning, dimensionality reduction, clustering, and cell annotation, similar in previous research [26–28]. After quality control and normalisation, we first identified highly variable genes in all cells. Principal component analysis (PCA) was then performed for feature extraction based on highly variable genes. The “ElbowPlot” function was used to filter the number of principal components (PCs). Finally, based on the selection of PCs, single cells were clustered and visualised in a Uniform Manifold Approximation and Projection (UMAP) fashion. The marker genes for each cluster were calculated and filtered by the “FindAllMarkers” function. The cell clusters were annotated according to the surface protein markers screened via flow cytometry in the original literature. Moreover, based on the UMAP algorithm, we projected the original tissue information of cells into clusters.

2.4. Ligand Receptor Analysis. We used CellPhoneDB to screen for possible cell-cell communication neuropeptide-related molecules in SFs as previous research [29–31]. The gene expression matrix of single-cell RNA sequencing (scRNA-seq) and the annotation of the ligand-receptor relationship pairs from the literature allowed systematic access to intercellular communication networks. Neuropeptide-related genes identified via single-cell analysis were used to filter these receptor and ligand molecules using intersection analysis.

2.5. Machine Learning-Based Variable Screening. Based on the cellular communication analysis, we obtained significant neuropeptide-related genes. Furthermore, m6A regulators that may act on neuropeptide-related genes were predicted by using the random forest model (RFM) and the support vector machine-recursive feature elimination (SVM-RFE). As indicated in prior investigations, RFM and SVM-RFE were used [32–34]. The m6A genes in the model were ranked by significance using the random forest model. SVM-RFE was used for screening m6A genes most closely related to neuropeptide genes [35].

2.6. Key m6A Regulatory Genes Were Identified by Intersection Analysis. Differential analysis of bulk RNA-seq between normal and RA databases screened out differentially expressed genes (DEGs) in RA. Subsequently, DE m6A-regulated genes in bulk RNA were identified. The m6A regulatory genes that are both differentially expressed

FIGURE 1: Continued.

(d)

(e)

FIGURE 1: Single-cell analysis preprocessing and downscaling and clustering process for GSE109449. (a) Data accusations after filtering of genes and cells. (b) Elbow plot showing that the inflection point occurs, suggesting that the first nine PCs can contain most signals. (c) All included cells are grouped into six clusters based on a clustering tree constructed based on the selected nine PCs. (d) Heat map showing the expression of the top 10 marker genes of the six clusters in single-cell samples. (e) Volcano plot showing differences in the expression of neuropeptide-related mRNAs among clustering-related marker genes. Abbreviation: PC: principal component.

FIGURE 2: Continued.

2.9. Statistical Analysis. All tests were two-sided, and $P < 0.05$ was considered significant. All analyses were performed using the R software (version 4.0.2, R Foundation for Statistical Computing, Vienna, Austria). The receiver operating characteristic (ROC) curves were created using the “pROC” package to evaluate the diagnostic performance of candidate m6A regulatory genes.

FIGURE 3: A machine learning-based gene screening process. (a) The random forest model of *GHR* prediction shows the importance of *GHR*-related 23 m6A enzymes. The genes are sorted by importance, and the m6A types to which they belong are shown in the legend. (b) SVM-RFE-based *GHR* prediction model for gene screening process. The final model accuracy was highest when five m6A regulatory genes were screened out. (c) ROC curves of SVM models constructed based on the screened five genes. (d) The variable selection process of the *NPR3* prediction model based on SVM-RFE showed the highest model prediction accuracy when 21 genes were included. Abbreviations: ROC: receiver operating characteristics; SVM-RFE: support vector machine-recursive feature elimination.

3. Results

3.1. ScRNA-seq Reveals a Heterogeneous Phenotype of SFs. To examine the possible role of SFs in RA, four samples from the GSE109449 dataset were used to explore the heterogeneity of fibroblasts. Figure 1(a) shows the quality control results of these cells as described in Seurat's manual [38]. A total of 384 cells were screened for inclusion in the subsequent analysis. Analysis of variance was performed to compare the genetic variability of SFs. Among the neuropeptide-related genes, significant transcriptional differences were found in *NPR3*, *BDKRB2*, *GHR*, and *CALCRL* (Figure 1(e)). The elbow plot demonstrated that the best clustering results of applying the first nine PCs can contain most signals (Figure 1(b)). The results of the clustering tree are shown in Figure 1(c), which shows a total of six cell clusters.

The heat map revealed the top 10 most important cell marker genes in each of these six cell clusters (Figure 1(d)).

3.2. Fibroblast Subpopulations and Neuropeptide-Related Genes. The UMAP plot of SFs revealed six cell clusters (Figure 2(a)). Three major cell surface proteins, namely, CD34, THY1, and CDH11, were used to annotate cell types in UMAP, and seven cell types were identified (Figure 2(b)). Furthermore, the relative expression of highly variable neuropeptide-related genes, namely, *NPR3*, *GHR*, *BDKRB2*, and *CALCRL*, was compared between cell clusters (Figure 2(c)). The expression of *NPR3* was significantly higher in cluster 2 than in other clusters. In addition, the expression of *GHR* was significantly higher in cluster 2, and the expression of *BDKRB2* was significantly higher in cluster 0. We found that the expression of *BDKRB2*, *NPR3*,

FIGURE 4: Combined analysis of screened m6A regulatory genes and DE mRNAs. (a) Venn plot showing the results of intersection analysis of SVM-RFE and DE mRNAs. A total of two m6A regulatory-related genes were screened. (b) Volcano plot showing the results of the differential analysis in bulk RNA. The two m6A regulatory genes are labelled in the graph. (c) Expression levels of *IGFBP2* and *METTL3* in UMAP. Abbreviations: DE: differentially expressed; SVM-RFE: support vector machine-recursive feature elimination.

and *GHR* was more pronounced compared to *CALCRL*. Therefore, cell annotations of *BDKRB2*, *NPR3*, and *GHR* were also demonstrated in the UMAP plot (Figure 2(d)).

3.3. Analysis of Neuropeptide-Related Ligands and Receptors. In these seven cell types, significantly different neuropeptides and their receptors were used to infer intercellular communication. As shown in Figure 2(e), the ligand–receptor interaction analysis reveals the pairing results of multiple neuropeptides and their receptors. *NPR3*, *NPPC*, *OSTN*, *NPPB*, and *NPPA* were found to interact in the communication cascade of SFs. In addition, there may be an interaction between CD34+THY1+CDH11+ cells and *GHR* from other cells.

3.4. Machine Learning Predicts Neuropeptide-Related m6A Factors. Using the random forest model, the ranking of the important m6A factors associated with *GHR* is shown in Figure 3(a). *FMR1*, *YTHDF3*, *IGFBP2*, and *RBMX* (readers) and *VIRMA* (writers) were identified as the top five significant m6A regulators. The results of the variable screening of the SVM-RFE model showed the highest accuracy of the

model for predicting *GHR* when five m6A regulatory genes were screened out (Figure 3(b)), with an AUC of 0.667 (Figure 3(c)). Similarly, the *NPR3* expression prediction model was most accurate when based on 21 variables (Figure 3(d)).

3.5. *IGFBP2* and *METTL3* Are Identified as Important m6A Regulators. The genes screened in the SVM-REF model were intersected with the DEGs in RA, and a total of two m6A regulatory genes were identified, namely, *METTL3* and *IGFBP2* (Figures 4(a) and 4(b)). The horizontal axis represents the fold change, with points further from the centre indicating a greater fold of difference; the vertical axis represents the FDR-adjusted *P* value, with points closer to the top indicating a more significant difference in expression between the two samples. However, in Figure 4(b), the difference between these two genes does not seem to be significant. But the next study revealed their potential significance. *METTL3* is an m6A writer, and *IGFBP2* is an m6A reader. The expression of *METTL3* and *IGFBP2* was assessed at the single-cell level using the UMAP algorithm (Figure 4(c)). *IGFBP2*+ fibroblasts were mainly found in

FIGURE 5: Expression characteristics of *IGFBP2* and *METTL3*. (a) UMAP of the initial sample information. (b) Upregulated *IGFBP2* and downregulated UMAP of *METTL3*. (c) The expression levels of *IGFBP2* in the six clusters. Among them, a slight increase in *IGFBP2* expression level was seen in cluster 2. (d) Expression levels of *METTL3* in six clusters. Among them, a decrease in *METTL3* expression level was seen in cluster 3.

RA9 and OA5 samples (Figure 5(a)). Volcanic map analysis revealed elevated expression of *IGFBP2* in cluster 2 (thought to be *IGFBP2*+) and downregulation of *METTL3* in cluster 3 (speculated to be *METTL3*-) (Figure 5(b)). Violin plots revealed the expression levels of *METTL3* and *IGFBP2* in six cell clusters (Figures 5(c) and 5(d)). *METTL3* cells were present in both RA and OA samples. The combined analysis demonstrated in Figure 2(d) and Figure 5(b) indicated that both *IGFBP2* and *GH2* were upregulated in cluster 2. Figures 2(c) and 5(d) demonstrate that the expression of *NPR3*, *GH2*, *BDKRB2* and *CALCRL* was significantly decreased in cluster 3 along with *METTL3* downregulation, suggesting that *METTL3* is an important regulator of the aforementioned four neuropeptide-related genes. Furthermore, in cluster 1, *NPR3* was significantly upregulated; however, no significant changes were observed in the expression of *IGFBP2* and *METTL3*, suggesting that other m6A factors may regulate posttranscriptional modifications of *NPR3*.

3.6. GSEA and Clinical Analysis of *IGFBP2* and *METTL3*. GSEA was performed to further assess the possible functions of *IGFBP2* and *METTL3* (Figure 6). *IGFBP1* upregulation was found to be accompanied by the upregulation of keratinisation and CD22-mediated BCR regulatory pathways. This finding suggests that *IGFBP2* is involved in keratinisation and immune behaviour in RA. G alpha(s) signalling, keratinisation, and systemic lupus erythematosus pathways were downregulated in cells with downregulated *METTL3*. This finding suggests that different m6A factors in RA play different or even opposite roles in different SFs. The qRT-PCR results of the clinical cohort revealed that *IGFBP2* was elevated in RA SFs compared with the healthy controls (HCs) ($P = 0.008$), and *METTL3* was downregulated in RA SFs compared with HCs ($P = 0.027$) (Figure 7). Therefore, we speculate that the m6A methylation-related genes *IGFBP2* and *METTL3* may influence the interaction between SFs by regulating the neuropeptides *GHR* and *NPR2*, thus contributing to disease progression in RA.

FIGURE 6: Gene set enrichment analysis of *IGFBP2* and *METTL3*. (a) Enrichment of upregulated functional pathways in samples with *IGFBP2* upregulation. (b) Downregulated functional pathways in samples with *METTL3* downregulation.

FIGURE 7: Results of the qRT-PCR in clinical cohorts: expression levels of *IGFBP2* and *METTL3* in healthy controls and rheumatoid arthritis synovial fibroblast samples. *IGFBP2* was elevated in RA compared with HCs ($P < 0.05$). *METTL3* was downregulated in RA compared with HCs ($P < 0.05$). Abbreviations: HC: health control; RA: rheumatoid arthritis; qRT-PCR: quantitative reverse transcription polymerase chain reaction.

4. Discussion

In this study, using single-cell analysis and machine learning, we determined the differential expression of *GHR* and *NPR2* in SFs. The m6A methylation-related genes *IGFBP2* and *METTL3* are thought to influence the interaction between SFs by regulating the neuropeptides *GHR* and *NPR2*.

We determined the intercellular heterogeneity of SFs via single-cell RNA-seq analysis. Cell-cell communication simulations were performed to find possible neuropeptide-associated ligand-receptor pairs among the annotated SF subpopulations. The results revealed that the neuropeptide-related genes *GHR* and *NPR3* belonged to both cluster marker genes and screened ligand-receptor pairs. Subsequently, we used machine learning to predict m6A factors that may act on *GHR* and *NPR3*. In addition, RA-related genes were identified via differential analysis of RNA. Therefore, after the intersection analysis, we confirmed the possible important roles of *IGFBP2* and *METTL3*. *IGFBP2*+ fibroblasts were mainly found in RA and OA samples, which suggested heterogeneity in *IGFBP2* expression at the individual level. In cluster 3, *NPR3*, *GH2*, *BDKRB2*, and *CALCRL* were significantly decreased along with *METTL3* downregulation, suggesting that *METTL3* is an important regulator of the aforementioned four neuropeptide-related genes. In cluster 2, both *IGFBP2* and *GH2* were upregulated. In addition, in cluster 1, *NPR3* was significantly upregulated; however, no significant changes were observed in the expression of *IGFBP2* and *METTL3*, suggesting that other m6A factors regulate posttranscriptional modifications of *NPR3*. To the best of our knowledge, we report for the first time the possible role of *GH2* and *NPR3* in the progression of RA. Therefore, the significance and mechanism of action of the differential expression of *GH2* and *NPR3* between different SFs require further analysis and validation.

METTL3 is an important m6A catalase. Previous studies have shown that *METTL3* can enhance RNA stability, thereby affecting cell division [39]. *METTL3* reduction can also result in m6A dysregulation leading to neurodegeneration in Alzheimer's disease [40]. In our study, we found that

METTL3 downregulation was accompanied by a significant decrease in neuropeptide-related mRNAs, such as *NPR3*, *GH2*, *BDKRB2*, and *CALCRL* in cluster 3.

IGFBP2 was found to be elevated in serum samples from the RA cohort, suggesting that *IGFBP2* may have an important role in the pathogenesis of RA [41]. Our study further demonstrates that *IGFBP2* is also significantly heterogeneous across individuals and subgroups of SFs. Moreover, we observed that *IGFBP2* and *GH2* were upregulated in cluster 2, suggesting that *IGFBP2* acts through the upregulation of *GH2*.

The development of single-cell sequencing has offered new methods to understand and study the diversity and function of cell subpopulations [21]. In this study, we examined the potential mechanisms of neuropeptides and m6A in RA using single-cell analysis and machine learning. However, data were not validated at the single-cell level. And the cell–cell communication analysis was performed on SFs, which may not be completely consistent with the way neuropeptides are regulated in vivo. In this study, we proposed a new approach to investigating the pathogenesis of RA. In the future, combined with spatial transcriptomic analysis, single-cell technology will help to better understand this disease. Better experimental designs and clinical studies to understand and confirm the involvement of these factors in RA development were still required.

5. Conclusion

We discovered neuropeptide-related molecules and m6A factors with key regulatory activities in RA with the help of single-cell analysis and machine learning. *GHR* and *NPR2* may play a role in the pathophysiological functional transformation of SFs. Through machine learning, the m6A factors, *METTL3* and *IGFBP2*, were found to regulate *GHR* and *NPR2* potentially. In clinical cohorts, *IGFBP2* was elevated in RA SFs, while *METTL3* was downregulated. This study may provide a basis for future studies to identify pathogenic cell subpopulations in RA and other complex diseases.

Abbreviations

UMAP:	Uniform Manifold Approximation and Projection for Dimension Reduction
RA:	Rheumatoid arthritis
m ⁶ A:	N6-Methyladenosine
SVM-RFE:	Support vector machine-recursive feature elimination
SF:	Synovial fibroblasts
FLS:	Fibroblast-like synoviocytes.

Data Availability

The public datasets generated and analysed during the present study are available from GSE109449 and GSE21959.

Ethical Approval

This study was approved by the Institutional Ethics Review Board of our hospital.

Consent

Informed written consent was obtained from all the patients.

Conflicts of Interest

The authors declare that there are no competing interests.

Authors' Contributions

Jianwei Xiao and Xu Cai contributed equally to this work.

Acknowledgments

The authors wish to thank all the patients and staff who participated in this study. The study was supported by funding from Shenzhen Futian Healthcare Research Project (FTWS2020046, FTWS2020053, FTWS2021026, and FTWS2021064) and Chinese Medicine Research Project of Traditional Chinese Medicine Bureau of Guangdong Province (20221342).

References

- [1] G. Nygaard and G. S. Firestein, "Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes," *Nature Reviews Rheumatology*, vol. 16, pp. 316–333, 2020.
- [2] M. V. Nemtsova, D. V. Zaletaev, I. V. Bure et al., "Epigenetic changes in the pathogenesis of rheumatoid arthritis," *Frontiers in Genetics*, vol. 10, p. 570, 2019.
- [3] T. Pap, B. Dankbar, C. Wehmeyer, A. Korb-Pap, and J. Sherwood, "Synovial fibroblasts and articular tissue remodelling: role and mechanisms," *Seminars in Cell & Developmental Biology*, vol. 101, pp. 140–145, 2020.
- [4] A. Filer, "The fibroblast as a therapeutic target in rheumatoid arthritis," *Current Opinion in Pharmacology*, vol. 13, pp. 413–419, 2013.
- [5] A. Filer, L. S. Ward, S. Kemble et al., "Identification of a transitional fibroblast function in very early rheumatoid arthritis," *Annals of the Rheumatic Diseases*, vol. 76, pp. 2105–2112, 2017.
- [6] H. Tsuchiya, M. Ota, and K. Fujio, "Multiomics landscape of synovial fibroblasts in rheumatoid arthritis," *Inflammation and Regeneration*, vol. 41, p. 7, 2021.
- [7] M. Ramirez-Villafañá, A. M. Saldaña-Cruz, J. A. Aceves-Aceves et al., "Serum Neuropeptide Y Levels Are Associated with TNF- α Levels and Disease Activity in Rheumatoid Arthritis," *Journal of Immunology Research*, vol. 2020, Article ID 8982163, 7 pages, 2020.
- [8] T. M. O'Connor, J. O'Connell, D. I. O'Brien, T. Goode, C. P. Bredin, and F. Shanahan, "The role of substance P in inflammatory disease," *Journal of Cellular Physiology*, vol. 201, no. 2, pp. 167–180, 2004.
- [9] C. H. Stenström, H. Alexanderson, I. Lundberg, T. Lundberg, E. Theodorsson, and R. Nisell, "Exercise and variations in

- neuropeptide concentrations in rheumatoid arthritis," *Neuropeptides*, vol. 33, pp. 260–264, 1999.
- [10] M. Fusco, S. D. Skaper, S. Coaccioli, G. Varrassi, and A. Paladini, "Degenerative joint diseases and neuroinflammation," *Pain Practice*, vol. 17, pp. 522–532, 2017.
 - [11] S. Niissalo, M. Hukkanen, S. Imai, J. Törnwall, and Y. T. Konttinen, "Neuropeptides in experimental and degenerative arthritis," *Annals of the New York Academy of Sciences*, vol. 966, pp. 384–399, 2002.
 - [12] C. Ospelt, S. Gay, and K. Klein, "Epigenetics in the pathogenesis of RA," *Seminars in Immunopathology*, vol. 39, pp. 409–419, 2017.
 - [13] C. Zeng, W. Huang, Y. Li, and H. Weng, "Roles of METTL3 in cancer: mechanisms and therapeutic targeting," *Journal of Hematology & Oncology*, vol. 13, p. 117, 2020.
 - [14] H. Zhao, S. Pan, J. Duan et al., "Integrative analysis of m6A regulator-mediated RNA methylation modification patterns and immune characteristics in lupus nephritis," *Frontiers in Cell and Development Biology*, vol. 9, article 724837, 2021.
 - [15] X. Jiang, B. Liu, Z. Nie et al., "The role of m6A modification in the biological functions and diseases," *Signal Transduction and Targeted Therapy*, vol. 6, p. 74, 2021.
 - [16] S. Zaccara, R. J. Ries, and S. R. Jaffrey, "Reading, writing and erasing mRNA methylation," *Nature Reviews. Molecular Cell Biology*, vol. 20, pp. 608–624, 2019.
 - [17] H. Shi, J. Wei, and C. He, "Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers," *Molecular Cell*, vol. 74, pp. 640–650, 2019.
 - [18] Y. Yang, P. J. Hsu, Y.-S. Chen, and Y.-G. Yang, "Dynamic transcriptomic m6A decoration: writers, erasers, readers and functions in RNA metabolism," *Cell Research*, vol. 28, pp. 616–624, 2018.
 - [19] Z. Shulman and N. Stern-Ginossar, "The RNA modification N6-methyladenosine as a novel regulator of the immune system," *Nature Immunology*, vol. 21, pp. 501–512, 2020.
 - [20] D. Fan, Y. Xia, C. Lu et al., "Regulatory role of the RNA N6-methyladenosine modification in immunoregulatory cells and immune-related bone homeostasis associated with rheumatoid arthritis," *Frontiers in Cell and Development Biology*, vol. 8, article 627893, 2021.
 - [21] H. L. Carr, J. D. Turner, T. Major, D. Scheel-Toellner, and A. Filer, "New developments in transcriptomic analysis of synovial tissue," *Front Med (Lausanne)*, vol. 7, p. 21, 2020.
 - [22] M. Jiang, Y. Li, C. Jiang, L. Zhao, X. Zhang, and P. E. Lipsky, "Machine learning in rheumatic diseases," *Clinical Reviews in Allergy and Immunology*, vol. 60, pp. 96–110, 2021.
 - [23] F. Mizoguchi, K. Slowikowski, K. Wei et al., "Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis," *Nature Communications*, vol. 9, p. 789, 2018.
 - [24] M. J. del Rey, E. Izquierdo, A. Usategui et al., "The transcriptional response of normal and rheumatoid arthritis synovial fibroblasts to hypoxia," *Arthritis and Rheumatism*, vol. 62, no. 12, pp. 3584–3594, 2010.
 - [25] M. D. Robinson, D. J. McCarthy, and G. K. Smyth, "edgeR: a Bioconductor package for differential expression analysis of digital gene expression data," *Bioinformatics*, vol. 26, pp. 139–140, 2010.
 - [26] T. Stuart, A. Butler, P. Hoffman et al., "Comprehensive integration of single-cell data," *Cell*, vol. 177, pp. 1888–1902.e21, 2019.
 - [27] P. Zhang, S. Nan, X. Duan, L. Wang, X. Sun, and H. Zheng, "Relationship between Expression of Plasma lncRNA-HEIH and Prognosis in Patients with Coronary Artery Disease," *Disease Markers*, vol. 2021, Article ID 5662080, 5 pages, 2021.
 - [28] Y. Chen, C. Chen, X. Xiao, Z. Huang, X. Huang, and W. Yao, "TNF- α Induces Neutrophil Apoptosis Delay and Promotes Intestinal Ischemia- Reperfusion-Induced Lung Injury through Activating JNK/FoxO3a Pathway," *Oxidative Medicine and Cellular Longevity*, vol. 2021, Article ID 8302831, 13 pages, 2021.
 - [29] M. Efremova, M. Vento-Tormo, S. A. Teichmann, and R. Vento-Tormo, "CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes," *Nature Protocols*, vol. 15, pp. 1484–1506, 2020.
 - [30] W.-W. Lin, L. T. Xu, Y. S. Chen, K. Go, C. Sun, and Y. J. Zhu, "Single-cell transcriptomics-based study of transcriptional regulatory features in the mouse brain vasculature," *BioMed Research International*, vol. 2021, Article ID 7643209, 15 pages, 2021.
 - [31] R. Huang, T. Meng, R. Zhu et al., "The integrated transcriptome bioinformatics analysis identifies key genes and cellular components for spinal cord injury-related neuropathic pain," *Frontiers in Bioengineering and Biotechnology*, vol. 8, p. 101, 2020.
 - [32] X. R. Kang, B. Chen, Y. S. Chen et al., "A prediction modeling based on SNOT-22 score for endoscopic nasal septoplasty: a retrospective study," *PeerJ*, vol. 8, article e9890, 2020.
 - [33] Y. S. Chen, Y. X. Cai, X. R. Kang et al., "Predicting the risk of sarcopenia in elderly patients with patellar fracture: development and assessment of a new predictive nomogram," *PeerJ*, vol. 8, article e8793, 2020.
 - [34] J. Wu, J. Qin, L. Li et al., "Roles of the immune/methylation/autophagy landscape on single-cell genotypes and stroke risk in breast cancer microenvironment," *Oxidative Medicine and Cellular Longevity*, vol. 2021, Article ID 5633514, 32 pages, 2021.
 - [35] M.-L. Huang, Y.-H. Hung, W. M. Lee, R. K. Li, and B.-R. Jiang, "SVM-RFE based feature selection and Taguchi parameters optimization for multiclass SVM classifier," *ScientificWorld-Journal*, vol. 2014, article 795624, 10 pages, 2014.
 - [36] G. Yu, L.-G. Wang, Y. Han, and Q.-Y. He, "clusterProfiler: an R package for comparing biological themes among gene clusters," *OMICS: A Journal of Integrative Biology*, vol. 16, no. 5, pp. 284–287, 2012.
 - [37] K. J. Livak and T. D. Schmittgen, "Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the $2^{-\Delta\Delta C_T}$ Method," *Methods*, vol. 25, no. 4, pp. 402–408, 2001.
 - [38] T. Ilicic, J. K. Kim, A. A. Kolodziejczyk et al., "Classification of low quality cells from single-cell RNA-seq data," *Genome Biology*, vol. 17, p. 29, 2016.
 - [39] H. Mu, T. Zhang, Y. Yang et al., "METTL3-mediated mRNA N6-methyladenosine is required for oocyte and follicle development in mice," *Cell Death & Disease*, vol. 12, p. 989, 2021.
 - [40] F. Zhao, Y. Xu, S. Gao et al., "METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer's disease through aberrant cell cycle events," *Molecular Neurodegeneration*, vol. 16, p. 70, 2021.
 - [41] S. Vordenbäumen, A. Lueking, P. Budde et al., "Sequential high-content profiling of the IgG-autoantibody repertoire reveals novel antigens in rheumatoid arthritis," *Arthritis Research & Therapy*, vol. 18, p. 235, 2016.